Association of Interleukin-10 −3575T>A and −1082A>G polymorphisms with non-Hodgkin lymphoma susceptibility: a comprehensive review and meta-analysis

[1]  Jing He,et al.  The Association Between NQO1 Pro187Ser Polymorphism and Urinary System Cancer Susceptibility: A Meta-Analysis of 22 Studies , 2015, Cancer investigation.

[2]  C. Ng,et al.  Analysis of interleukin-10 promoter single nucleotide polymorphisms and risk of non-Hodgkin lymphoma in a Malaysian population , 2015, Leukemia & lymphoma.

[3]  Xiao-Yu Liao,et al.  Association of MTHFR C677T and A1298C polymorphisms with non-Hodgkin lymphoma susceptibility: Evidence from a meta-analysis , 2014, Scientific Reports.

[4]  C. Klein,et al.  Interleukin-10 receptor signaling in innate immune cells regulates mucosal immune tolerance and anti-inflammatory macrophage function. , 2014, Immunity.

[5]  Z. Magić,et al.  Association of interleukin-10, tumor necrosis factor-α and transforming growth factor-β gene polymorphisms with the outcome of diffuse large B-cell lymphomas , 2014, International Journal of Clinical Oncology.

[6]  Yunfeng Cheng,et al.  Upregulation of innate immune responses in a T cell/histiocyte-rich large B cell lymphoma patient with significant autoimmune disorders mimicking systemic lupus erythematosus , 2014, Annals of Hematology.

[7]  Jing He,et al.  Associations of Lys939Gln and Ala499Val polymorphisms of the XPC gene with cancer susceptibility: A meta‐analysis , 2013, International journal of cancer.

[8]  D. Miranda-Saavedra,et al.  The IL-10/STAT3-mediated anti-inflammatory response: recent developments and future challenges , 2013, Briefings in functional genomics.

[9]  N. Rothman,et al.  IL10 and TNF variants and risk of non-Hodgkin lymphoma among three Asian populations , 2013, International Journal of Hematology.

[10]  M. Borowiec,et al.  Polymorphisms of TNF and IL‐10 genes and clinical outcome of patients with chronic lymphocytic leukemia , 2013, Genes, chromosomes & cancer.

[11]  E. Smeland,et al.  Influence of polymorphisms in genes encoding immunoregulatory proteins and metabolizing enzymes on susceptibility and outcome in patients with diffuse large B-cell lymphoma treated with rituximab , 2013, Leukemia & lymphoma.

[12]  Peter Boyle,et al.  Occupational solvent exposure, genetic variation in immune genes, and the risk for non-Hodgkin lymphoma , 2013, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[13]  Menghong Sun,et al.  Tumor Necrosis Factor-α Induced Protein 8 Polymorphism and Risk of Non-Hodgkin’s Lymphoma in a Chinese Population: A Case-Control Study , 2012, PloS one.

[14]  M. Ziepert,et al.  Circulating Levels of TNF Receptor II Are Prognostic for Patients with Peripheral T-cell Non–Hodgkin Lymphoma , 2012, Clinical Cancer Research.

[15]  Menghong Sun,et al.  Polymorphisms in the XPG gene and risk of gastric cancer in Chinese populations , 2012, Human Genetics.

[16]  Andre Franke,et al.  SNPexp - A web tool for calculating and visualizing correlation between HapMap genotypes and gene expression levels , 2010, BMC Bioinformatics.

[17]  C. Hess,et al.  Natural killer-cell receptor polymorphisms and posttransplantation non-Hodgkin lymphoma. , 2010, Blood.

[18]  J. Margolick,et al.  Cytokine signaling pathway polymorphisms and AIDS-related non-Hodgkin lymphoma risk in the multicenter AIDS cohort study , 2010, AIDS.

[19]  G. Salles,et al.  Plasma TNF-α and IL-10 Level-Based Prognostic Model Predicts Outcome of Patients with Diffuse Large B-Cell Lymphoma in Different Risk Groups Defined by the International Prognostic Index , 2010, Archivum Immunologiae et Therapiae Experimentalis.

[20]  K. Humphreys,et al.  Genetic variation in chromosomal translocation breakpoint and immune function genes and risk of non-Hodgkin lymphoma , 2010, Cancer Causes & Control.

[21]  A. Hatzakis,et al.  Genetic variants in immunoregulatory genes and risk for childhood lymphomas , 2009, European journal of haematology.

[22]  S. Chanock,et al.  Common genetic variants in candidate genes and risk of familial lymphoid malignancies , 2009, British journal of haematology.

[23]  J. Cerhan,et al.  Organochlorine exposure, immune gene variation, and risk of non-Hodgkin lymphoma. , 2009, Blood.

[24]  J. Cerhan,et al.  Etiologic heterogeneity among non-Hodgkin lymphoma subtypes. , 2008, Blood.

[25]  J. Cerhan,et al.  Host immune gene polymorphisms in combination with clinical and demographic factors predict late survival in diffuse large B-cell lymphoma patients in the pre-rituximab era. , 2008, Blood.

[26]  A. Scarpa,et al.  Interleukin‐1B (IL1B) and interleukin‐6 (IL6) gene polymorphisms are associated with risk of chronic lymphocytic leukaemia , 2008, Hematological oncology.

[27]  K. Kuliczkowski,et al.  Interleukin-10 gene polymorphisms influence the clinical course of non-Hodgkin's lymphoma. , 2008, Tissue antigens.

[28]  E. González-Barca,et al.  Impact of interleukin-10 polymorphisms (−1082 and −3575) on the survival of patients with lymphoid neoplasms , 2007, Haematologica.

[29]  J. Cerhan,et al.  Sun exposure, vitamin D receptor gene polymorphisms and risk of non-Hodgkin lymphoma , 2007, Cancer Causes & Control.

[30]  J. Cerhan,et al.  Immune mechanisms in non-Hodgkin lymphoma: joint effects of the TNF G308A and IL10 T3575A polymorphisms with non-Hodgkin lymphoma risk factors. , 2007, Cancer research.

[31]  Yeon-Hee Park,et al.  Interleukin‐10 gene polymorphism influences the prognosis of T‐cell non‐Hodgkin lymphomas , 2007, British journal of haematology.

[32]  N. Rothman,et al.  Polymorphisms in immune function genes and risk of non-Hodgkin lymphoma: findings from the New South Wales non-Hodgkin Lymphoma Study. , 2007, Carcinogenesis.

[33]  W. Cozen,et al.  Altered Immunity as a Risk Factor for Non-Hodgkin Lymphoma , 2007, Cancer Epidemiology Biomarkers & Prevention.

[34]  R. Redon,et al.  Relative Impact of Nucleotide and Copy Number Variation on Gene Expression Phenotypes , 2007, Science.

[35]  M. Pfreundschuh,et al.  The interleukin-10 gene promoter polymorphism −1087AG does not correlate with clinical outcome in non-Hodgkin's lymphoma , 2007, Genes and Immunity.

[36]  G. Salles,et al.  Genetic polymorphisms in the proximal IL-10 promoter and susceptibility to non-Hodgkin lymphoma , 2007, Leukemia & lymphoma.

[37]  L. Beckmann,et al.  Gene polymorphisms in Toll-like receptors, interleukin-10, and interleukin-10 receptor alpha and lymphoma risk , 2006, Genes and Immunity.

[38]  A. Iolascon,et al.  Interleukin-10 - 1082 GG polymorphism influences the occurrence and the clinical characteristics of hepatitis C virus infection. , 2006, Journal of hepatology.

[39]  Nilanjan Chatterjee,et al.  Common genetic variants in proinflammatory and other immunoregulatory genes and risk for non-Hodgkin lymphoma. , 2006, Cancer research.

[40]  Peter Boyle,et al.  Cytokine polymorphisms in the Th1/Th2 pathway and susceptibility to non-Hodgkin lymphoma. , 2006, Blood.

[41]  R. Rosenquist,et al.  The interleukin-10 gene promoter polymorphism (-1082) does not correlate with clinical outcome in diffuse large B-cell lymphoma. , 2005, Blood.

[42]  N. Chiorazzi,et al.  Analysis of single nucleotide polymorphisms in the promoter region of interleukin-10 by denaturing high-performance liquid chromatography. , 2005, Journal of biomolecular techniques : JBT.

[43]  G. Salles,et al.  Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma. , 2004, Blood.

[44]  C. Chapman,et al.  Polymorphisms in the Interleukin 10 Gene Promoter are Associated with Susceptibility to Aggressive Non-Hodgkin's Lymphoma , 2003, Leukemia & lymphoma.

[45]  G Flandrin,et al.  The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[46]  R. Westendorp,et al.  Interleukin 10 secretion in relation to human IL-10 locus haplotypes. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[47]  G. Smith,et al.  Bias in meta-analysis detected by a simple, graphical test , 1997, BMJ.

[48]  D. Boomsma,et al.  Genetic influence on cytokine production and fatal meningococcal disease , 1997, The Lancet.

[49]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[50]  W. Haenszel,et al.  Statistical aspects of the analysis of data from retrospective studies of disease. , 1959, Journal of the National Cancer Institute.

[51]  Baoan Chen,et al.  The interleukin-10-1082A>G polymorphism and lymphoma risk: a meta-analysis. , 2014, Cancer biomarkers : section A of Disease markers.

[52]  Theodore R Holford,et al.  Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. , 2006, The Lancet. Oncology.

[53]  M. Rose-Zerilli,et al.  Interleukin-10 Polymorphisms, Cancer Susceptibility and Prognosis , 2005, Familial Cancer.

[54]  Clara D. Bloomfield,et al.  The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting--Airlie House, Virginia, November, 1997. , 2000, The hematology journal : the official journal of the European Haematology Association.

[55]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.